Pharmalink Enters Manufacturing Agreement for Nefecon(R)

Pharmalink Enters Manufacturing Agreement for Nefecon(R) PR Newswire STOCKHOLM, October 31, 2012 STOCKHOLM, October 31, 2012 /PRNewswire/ -- Pharmalink AB, a Swedish specialty pharma company, today announces it has entered into a contract with Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry for the manufacturing of Nefecon®, Pharmalink's lead product. Nefecon is being developed as the first on-label medication specifically aimed at addressing the underlying pathology of progressive IgA nephropathy, the most common form of primary glomerulonephritis and a leading cause of end-stage renal disease. The agreement covers the manufacturing of Nefecon and is an important step in progressing the product towards the market. No commercial terms were disclosed. Johan Häggblad, Managing Director of Pharmalink, said: "Despite the increasing recognition of IgA nephropathy as a significant cause of morbidity and mortality, no specific medications have been developed and introduced to the market. In that context, our development programme for Nefecon is seen as one of the most significant in IgA nephropathy clinical research. We have already shown positive results in an open-labelled Phase II trial evaluating Nefecon's safety and efficacy and, with Patheon, we will be working with one of the pharmaceutical industry's best- respected manufacturers as Nefecon advances towards pivotal trials.